Revolution Medicines SVP Cislini sells $158,599 in shares

Revolution Medicines SVP Cislini sold 765 shares of the company's stock on September 25, 2026, for a total of $158,599. The sale was executed under a pre-approved trading plan and occurred as the stock price has surged 344% in the past year. Following the sale, Cislini still holds 51,776 shares of Revolution Medicines common stock.

The stock is currently considered overvalued by InvestingPro analysis, and the company has recently seen significant attention following FDA approval of its drug Rasonque for treating second-line metastatic pancreatic ductal adenocarcinoma.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.